On January 7, 2021, two major pharmaceutical companies, Pfizer and Bristol Myers Squibb, announced a new agreement to co-promote Eliquis, a popular anticoagulant medication.

Eliquis, also known as apixaban, is used to prevent blood clots and reduce the risk of stroke in patients with atrial fibrillation. Since its approval by the Food and Drug Administration (FDA) in 2012, Eliquis has become one of the leading anticoagulant medications on the market, with sales reaching over $8 billion in 2019.

Under this new agreement, Pfizer and Bristol Myers Squibb will share responsibility for the marketing and promotion of Eliquis in the United States. The two companies already share commercialization rights for the medication outside of the U.S.

The partnership is expected to expand the reach and impact of Eliquis, as both companies bring their strengths and expertise to the table. Pfizer, with its strong marketing and sales capabilities, will focus on promoting Eliquis to healthcare providers and patients. Meanwhile, Bristol Myers Squibb, with its deep knowledge of cardiovascular diseases, will work on developing new clinical data and educational resources to support the drug.

In a joint statement, the two companies expressed their excitement about the partnership and their shared dedication to improving patient care. Michael Goettler, CEO of Pfizer`s Upjohn division, stated that “this agreement reflects our continued commitment to advancing patient care and expanding access to innovative medicines that respond to the needs of patients.”

The announcement of this partnership comes at a time of significant growth and development in the pharmaceutical industry. With the ongoing COVID-19 pandemic, there is an urgent need for innovative treatments and medications to address a range of health concerns.

Overall, the Eliquis Pfizer BMS agreement represents a significant step forward in the pharmaceutical industry and a promising opportunity for patients and healthcare providers. By combining their resources and expertise, Pfizer and Bristol Myers Squibb are paving the way for more effective and accessible treatments for cardiovascular disease and other health concerns.